TRANSCRIPTOMICS TECHNOLOGIES MARKET ANALYSIS

Transcriptome refers to a set of all the transcripts present in an individual or a population of cells. Transcripts comprise all types of ribonucleic acid (RNA) molecules namely, messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), and other non-coding RNA molecules.

Statistics:

The global transcriptomics technologies market is estimated to account for US$ 15,569.1 Mn in terms of value by the end of 2027.

Global Transcriptomics Technologies Market: Drivers

Approval and launch of microarrays is expected to propel growth of the global transcriptomics technologies market over the forecast period. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.

Moreover, initiatives to advance personalized medicine are also expected to aid in growth of the market. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database.

Statistics:

North America held dominant position in the global transcriptomics technologies market in 2019, accounting for 39.2% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Transcriptomics Technologies Market Share (%) Value, By Region, 2019

To learn more about this report, request sample copy

Global Transcriptomics Technologies Market: Restraints

Lack of efficient data analysis tools is expected to hinder growth of the market. With increasing technological advances, there has been a rising concern about data complexity post analysis of transcripts through sequencing platforms. Complex data management is one of the major limitations faced in transcriptome research. The data complexity increases with advances in the subsequent RNA analysis methodologies.

Moreover, complex processes involved in isolation of RNA from the tissue of interest are also expected to limit the market growth.

Global Transcriptomics Technologies Market: Opportunities

Increasing prevalence of cancer is expected to offer lucrative growth opportunities for players in the global transcriptomics technologies market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, development of new technologies is also expected to aid in growth of the market. For instance, in December 2019, PathogenDx, Inc. was awarded two US Patents for Tandem PCR + Microarray Hybridisation technology.

Statistics:

The global transcriptomics technologies market was valued at US$ 4,625.8 Mn  in 2019 and is forecast to reach a value of US$ 15,569.1 Mn by 2027 at a CAGR of 16.4% between 2020 and 2027.

Figure 2: Global Transcriptomics Technologies Market Value (US$ Mn), 2016 – 2027

To learn more about this report, request sample copy

Market Trends/Key Takeaways

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in May 2019, Siemens Healthineers launched its new Atellica CH Enzymatic Hemoglobin A1c Assay to for diagnosing and monitoring diabetes.

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in April 2020, Bio-Rad Laboratories, Inc. acquired Celsee, Inc., a developer of instruments and consumables for the isolation, detection, and analysis of single cells.

Global Transcriptomics Technologies Market: Competitive Landscape

Major players operating in the global transcriptomics technologies market include, Affymetrix, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Illumina, Inc., F. Hoffmann-La Roche Ltd., Life Technologies Corporation, LC Sciences, LLC, and Qiagen N.V.

Global Transcriptomics Technologies Market: Key Developments

Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in March 2020, Illumina, Inc. partnered with IDbyDNA Inc., a metagenomics technology company, for R&D of next-generation sequencing-based workflows.

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in June 2018, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its Dako PD-L1 IHC 22C3 pharmDx assay used for determining PD-L1 expression in cervical cancer.